title: Acrylic cement added with antiblastics in the treatment of bone metastases. Ultrastructural and in vitro analysis.
abstract: An increased long-term survival of patients with alignant tumours also increases the possibility of the development of skeletal metastases and pathological fractures. The management of bone metastases includes the removal of gross disease and the administration of local adjuvants. We have investigated the possibility of adding antiblastic drugs to acrylic cement. Cylinders of acrylic cement were manufactured containing three different antiblastic drugs, methotrexate, cisplatin and doxorubicin. We performed in vitro analysis on MCF-7 human breast cancer cells in order to evaluate the biological effect of the mixtures and surface analysis of the acrylic cement-cisplatin cylinders using energy-dispersive x-ray analysis (EDAX). All drugs were released in an active form from the cement. Each drug had a different effect on cell viability. Doxorubicin had the greatest effect on breast cancer cells. Surface analysis showed that antiblastic drugs were present in the form of granules. These results confirm the potential of antiblastic-loaded cement as a possible adjuvant in the local treatment of bone metastases. Further studies should be undertaken to determine whether the release of antiblastic drugs from cement is elution or if they are only released from the surface.
authors.affiliation: Department of Pathology, Catholic University, Largo F. Vito, 1-00136 Rome, Italy.
authors.forename: M A
authors.initials: MA
authors.lastname: Rosa
authors.forename: G
authors.initials: G
authors.lastname: Maccauro
authors.forename: A
authors.initials: A
authors.lastname: Sgambato
authors.forename: R
authors.initials: R
authors.lastname: Ardito
authors.forename: G
authors.initials: G
authors.lastname: Falcone
authors.forename: V
authors.initials: V
authors.lastname: De Santis
authors.forename: F
authors.initials: F
authors.lastname: Muratori
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001843:Bone Cements; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage; D004396:Coloring Agents; D004317:Doxorubicin / Q000008:administration & dosage; D004337:Drug Carriers; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D020366:Methylmethacrylate; D008855:Microscopy, Electron, Scanning / Q000379:methods; D013778:Tetrazolium Salts; D013844:Thiazoles; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D001843:Bone Cements; D004396:Coloring Agents; D004337:Drug Carriers; D013778:Tetrazolium Salts; D013844:Thiazoles; D020366:Methylmethacrylate; D004317:Doxorubicin; C022616:thiazolyl blue; D002945:Cisplatin; D008727:Methotrexate